Hepatitis C Treatment & Management

@inproceedings{Andronescu2014HepatitisCT,
  title={Hepatitis C Treatment & Management
},
  author={Dan Valentin Andronescu and Sorina Diaconu and Nicoleta Tiuca and R. Purcarea and CI Andronescu},
  booktitle={Journal of medicine and life},
  year={2014}
}
Combination therapy with pegylated interferon alfa (PEG-IFN alfa) and the nucleoside analogue ribavirin is the current standard of care in patients infected with hepatitis C virus (HCV). Patients with HCV genotype 1 have a much less favorable response to therapy and are treated for 12 months, compared with patients infected with genotypes 2 and 3, in whom a 6-month course of therapy is sufficient. If viremia is present after 6 months, additional therapy has a negligible benefit, and treatment… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  • The New England journal of medicine
  • 2002
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Liver Diseases. The Washington Manual of Medical Therapeutics 34th Edition

MK Rude, T Rude, M Melman.Lisker
  • 2014
VIEW 1 EXCERPT

Benefits from sustained virological response to pegylated interferon plus ribavirin in hiv/hcv-coinfected patients with compensated cirrhosis

JA Mira, A Rivero-Juárez, +3 authors ID Santos-Gil
  • Clin Infect Dis. Feb
  • 2013
VIEW 1 EXCERPT

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2013

Hepatitis C. Treatment & Management; Updated

VK Dhawan
  • Sep 18,
  • 2013
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…